{"Title": "Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours", "Year": 2019, "Source": "Br. J. Cancer", "Volume": "120", "Issue": 4, "Art.No": null, "PageStart": 379, "PageEnd": 386, "CitedBy": 4, "DOI": "10.1038/s41416-019-0377-x", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85060737070&origin=inward", "Abstract": "\u00a9 2019, The Author(s). Background: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. Methods: Eligible patients with ECOG PS 0\u20131 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5 mg/m 2 , with dose escalation in a 3 + 3 design. The dose-expansion phase evaluated eribulin-LF in select tumour types. Primary objectives: maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF. Results: Totally, 58 patients were enroled (median age = 62 years). The MTD was 1.4 mg/m 2 (Schedule 1) or 1.5 mg/m 2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30 h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses. Conclusions: Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed.", "AuthorKeywords": null, "IndexKeywords": ["Adult", "Aged", "Drug Compounding", "Female", "Furans", "Humans", "Ketones", "Liposomes", "Male", "Maximum Tolerated Dose", "Middle Aged", "Neoplasms"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85060737070", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"55342052000": {"Name": "Evans T.R.J.", "AuthorID": "55342052000", "AffiliationID": "60001490", "AffiliationName": "University of Glasgow"}, "40162764100": {"Name": "Zubairi I.", "AuthorID": "40162764100", "AffiliationID": "60000265", "AffiliationName": "Beatson West of Scotland Cancer Centre"}, "56182088300": {"Name": "Sweeting L.", "AuthorID": "56182088300", "AffiliationID": "60000265", "AffiliationName": "Beatson West of Scotland Cancer Centre"}, "14046800300": {"Name": "Dean E.", "AuthorID": "14046800300", "AffiliationID": "60028784", "AffiliationName": "The Christie NHS Foundation Trust"}, "8912143100": {"Name": "Barriuso J.", "AuthorID": "8912143100", "AffiliationID": "60028784", "AffiliationName": "The Christie NHS Foundation Trust"}, "17135468000": {"Name": "Molife L.R.", "AuthorID": "17135468000", "AffiliationID": "60017166, 60010337", "AffiliationName": "The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research"}, "56966036700": {"Name": "Lopez J.", "AuthorID": "56966036700", "AffiliationID": "60017166, 60010337", "AffiliationName": "The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research"}, "7005465122": {"Name": "Ranson M.", "AuthorID": "7005465122", "AffiliationID": "60028784", "AffiliationName": "The Christie NHS Foundation Trust"}, "23003988800": {"Name": "El-Khouly F.", "AuthorID": "23003988800", "AffiliationID": "60109234", "AffiliationName": "UCL Cancer Institute"}, "24492766900": {"Name": "Savulsky C.", "AuthorID": "24492766900", "AffiliationID": "60018508", "AffiliationName": "Eisai Ltd."}, "6602472929": {"Name": "Reyderman L.", "AuthorID": "6602472929", "AffiliationID": "60012470", "AffiliationName": "Eisai Inc."}, "57205596131": {"Name": "Jia Y.", "AuthorID": "57205596131", "AffiliationID": "60012470", "AffiliationName": "Eisai Inc."}, "22940493900": {"Name": "Greystoke A.", "AuthorID": "22940493900", "AffiliationID": "60026712, 60006222", "AffiliationName": "Northern Institute for Cancer Research, Newcastle University"}, "8771515300": {"Name": "Kristeleit R.", "AuthorID": "8771515300", "AffiliationID": "60109234", "AffiliationName": "UCL Cancer Institute"}}}